Advertisement

Antithrombotic Therapy for Cardiac Disease

  • Joseph ShatzelEmail author
Chapter

Abstract

This chapter reviews primary and secondary prevention of ischemic heart disease. Also reviewed is stroke prevention in atrial fibrillation and in abnormal or prosthetic cardiac valves.

Keywords

Non-ST elevation MI Acute coronary syndrome Atrial fibrillation Prosthetic cardiac valve Thrombolytic therapy 

Suggested Reading

  1. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society. Heart Rhythm. 2019.Google Scholar
  2. Larson EA, German DM, Shatzel J, DeLoughery TG. Anticoagulation in the cardiac patient: a concise review. Eur J Haematol. 2019;102(1):3–19.CrossRefGoogle Scholar
  3. Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention, 2011 ACCF/AHA guideline for coronary artery bypass graft surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction, 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes, and 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery. Circulation. 2016;134(10):e123-155.CrossRefGoogle Scholar
  4. Lip GY. Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why? Eur Heart J. 2013;34(14):1041–9.  https://doi.org/10.1093/eurheartj/ehs435. Epub 2012 Dec 20.CrossRefPubMedGoogle Scholar
  5. Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation. 2017;135(25):e1159–95.CrossRefGoogle Scholar
  6. Vandvik PO, Lincoff AM, Gore JM, Gutterman DD, Sonnenberg FA, Alonso-Coello P, Akl EA, Lansberg MG, Guyatt GH, Spencer FA. American College of Chest PhysiciansPrimary and secondary prevention of cardiovascular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e637S–68S.CrossRefGoogle Scholar
  7. Whitlock RP, Sun JC, Fremes SE, Rubens FD, Teoh KH. American College of Chest Physicians. Antithrombotic and thrombolytic therapy for valvular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e576S–600S.  https://doi.org/10.1378/chest.11-2305.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Division of Hematology/Medical Oncology, Department of Medicine and Biomedical EngineeringOregon Health & Sciences UniversityPortlandUSA

Personalised recommendations